SÉMINAIRE GSMN DES MÉDECINS Samedi 7 mars 2015 GSMN 1

Transcription

1 SÉMINAIRE GSMN DES MÉDECINS 2015 Samedi 7 mars 2015 GSMN 1

2 DR NICOLAS DURAND CEO ABIONIC GSMN 2

3 Nanotechnology for healthcare experts Dr. Nicolas Durand, CEO Copyright Abionic

4 INPUT OUTPUT Company presentation Breakthrough Nanofluidic Technology Adhesion layer Capture molecule Blocker protein Patient analyte (if present) Fluorescently labeled secondary antibody Other patient proteins Hundreds of nanometers LASER

5 Our vision Based on a new disruptive nanotechnology, Abionic is committed to improving the world of diagnostics through innovation by providing a rapid quantitative platform to medical practitioners. Abionic s strategic vision is developing through 2 axis: we are now changing the game in allergy diagnostic;

6 Allergy: 5th leading Chronic Disease Skin Prick Tests using painful reactions on the skin of patients Laboratory Tests using vials filled with blood Not accurate! Time consuming!

7 The abioscope First results within 5 minutes Quantitative Total & specific IgE results Intuitive easy handling Pending 510(k)

8 The abiokit One drop of whole blood (50µl) Personalized capsule CHF 20 / allergen RFID secured Component resolved diagnostics

9 A new concept of personalized medicine E-shop from Abionic s website:

10 Example of capsule configuration The respiratory capsule : Total IgE Amb a 1 (Ragweed) Bet v 1 (Birch) Der p 1 (Mite) Bet v 2 (Birch) Der p 2 (Mite) Phl p 1 (Timothy grass) Fel d 1 (Cat) Phl p 5 (Timothy grass) Can f 1 (Dog) Ole e 1 (Olive) «A capsule composed of the main respiratory allergens is of great interest for most allergists» Prof. François Spertini

11 Analytical performance 450 human samples compared with gold standard: Specificity: 88.7% Sensitivity: 87.5% Accuracy: 88.2% Limit of Detection: 9.9 ku/l Upper limit of detection: 400 ku/l Traceability: calibrated with WHO intern. standard IgE Compatible with human whole blood, serum and plasma

12 abioguide mobile application iphone, ipad & Android platforms Send report to printer or by (PDF) Access to allergen database Generate simplified report for patient Allergy profile pocket card for patient

13 First quantitative PoC device Versatility, analysis decentralization and rapidity Allergy Sepsis Asthma Next applications Phase 1 Feasibility analysis (management) Phase 2 Test development (R&D) Phase 3 Clinics & Scaleup (production) Phase 4 Commercializatio n (M&S) Time

14 A competent team for execution Dr. Nicolas Durand Dr. Iwan Märki Boris Iseli Dr. Fabien Rebeaud Founder & CEO Co-Founder & CTO Team 15 employees incl. 6 PhDs, strongly supported by: Prof. Spertini, Swiss Key Opinion Leader Prof. Lasser, EPFL, Co-Founder & Chairman Urs Amstutz, Allergy diagnosis market expert Tim Dyer, CEO/Co-founder Addex Therapeutics Walid Hanna, MedHoldings General Partner CFO Head of Biology

15 Thank you for your attention Abionic SA EPFL Innovation Park, Building B 1015 Lausanne Switzerland info@abionic.com

16